NCT01039103 - Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Acute Exacerbation of Remitting Relapsing Multiple SclerosisClinically Isolated Syndrome

Interventions

DRUG

PEG-liposomal prednisolone sodium phosphate

PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1

DRUG

Methylprednisolone

Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3

Trial Locations (8)

Nationaal MS Centrum, Melsbroek

Departement Neurologie AZ St Jan AV, Bruges

St. Josef Hospital der Ruhr, Bochum

Klinikum Rechts der Isar der technischen Universitaet Muenchen, Neurologische Klinik und Poliklinik, München

Krankenhaus Hohe Warte, Neurologische Klinik, Bayreuth

Revalidatie & MS-centrum Overpelt, Overpelt

Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok

Diagnomed-Clinical Research Sp. z o.o., Katowice